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ABSTRACT
Objectives: Musculoskeletal (MSK) pain and hypersomnolence (HPS) are very disabling conditions 
that may share some pathophysiological factors. This study aimed to evaluate the interaction 
between MSK pain and HPS and its association with mood symptoms, fatigue, quality of  life, 
and both objective and subjective sleep quality. Design: Cross-sectional study. Setting: General 
population based sample. Participants: 510 individuals from EPISONO cohort, São Paulo (Brazil). 
Measurements: All participants completed questionnaires, had clinical assessment and underwent 
a full-night polysomnography. HPS was defined according to Epworth Sleepiness Scale while the 
presence of  MSK pain was defined by structured questionnaire. The sample was allocated into 4 
groups: control (CTRL, n=281), HPS (n=141), MSK (n=50), and both conditions (HPS+MSK, 
n=38). Results: MSK pain and HPS by themselves were associated with worse mood symptoms 
and quality of  life. However, individuals with both associated conditions (HPS+MSK) presented 
higher frequencies of  moderate to severe depression (44.1%) and anxiety symptoms (45.7%), as well 
as an additional decrease in quality of  life compared to the other groups. There were no differences 
between HPS+MSK and MSK groups in objective sleep pattern. With regard to subjective sleep, 
HPS+MSK presented a higher prevalence of  sleep attacks and cataplexy compared to all other 
groups. Conclusions: The combination of  MSK pain and HPS was associated with worse mood 
symptoms, quality of  life and HPS-related features. This study suggests that sleepiness may be an 
important symptom to be investigated and treated in MSK pain-related conditions for a better 
quality of  life.
Keywords: Sleep; Musculoskeletal Pain; Disorders of  Excessive Somnolence; Mood Disorders; 
Quality of  Life.
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INTRODUCTION
In adults, the incidence of  chronic pain is around 10% 
per year, while its prevalence varies from 7% to 48%1,2 depend-
ing on the population investigated. Population-based studies 
suggest that chronic pain can be associated with age, female 
gender, socioeconomic level, among other factors3-5. Specifically 
for chronic musculoskeletal pain (MSK), the associated risk fac-
tors include female gender, aging, family history, depression, nu-
tritional status and sleep disturbances6-8.
Sleep and pain present a bidirectional relationship9,10. 
Sleep deprivation has been consistently associated with hyper-
algesia in both humans and animals6, while sleep disorders fre-
quently occur in pain-related conditions11. Nevertheless, other 
sleep disturbances such as hypersomnolence (HPS) have been 
much less studied in this context.
HPS is a transitory state between wake and sleep that can 
be defined as an exacerbated tendency of  the subject to fall asleep 
briefly in a given time if  circumstances permit12,13. The prevalence of  
diurnal HPS is estimated to affect 0.5%-5.0% of  adults14. HPS has 
been associated with several psychiatric and medical conditions such 
as neurological and cardiovascular comorbidities, substance abuse, 
and psychotropic drug13. Among the central disorders of  HPS, nar-
colepsy type 1 is the main sleep disturbance, characterized by the 
presence of  excessive daytime sleepiness, cataplexy and other rapid 
eye movement (REM) sleep phenomena, such as sleep paralysis and 
hypnagogic hallucinations15.
A few studies showed a relationship between HPS and 
MSK pain in adults16,17. Thus, we hypothesized that HPS could 
be negatively associated with physical, psychological and social 
well-being, as well as lower quality of  life in patients with MSK 
pain when compared to those without HPS. Therefore, the aim 
of  the current study was to evaluate the interaction between 
HPS and MSK pain on mood symptoms, sleep quality and sleep 
pattern, and quality of  life in a general population sample.
MATERIAL AND METHODS
Study population and sampling procedures
This study comprises a secondary analysis of  data from 
the EPISONO cohort18, an epidemiological study performed 
in the city of  São Paulo. It was used a three-stage cluster sam-
pling method to get a representative sample of  São Paulo’s adult 
population according to age, gender and socioeconomic class. 
Detailed information about sampling methodology has been 
already described elsewhere18. The study was approved by the 
University’s Institutional Ethics Committee (CEP#0593/06). 
As shown in Figure 1, the exclusion criteria of  this study con-
sisted of  missing data for MSK pain and/or somnolence as-
sessments; the presence of  pain located in other locations than 
back, over the body, joints, and legs. Overall, EPISONO in-
cluded 1,042 volunteers, from which 510 fitted the criteria of  
the current study, signed the informed consent form, answered 
questionnaires, had clinical assessment, and underwent a full-
night polysomnography (PSG).
Sociodemographic and clinical evaluation
The sociodemographic data was collected by Datafolha 
Institute at the volunteer’s house. Parameters such as age, sex, 
and monthly income were completed according to the Brazilian 
Economic Classification Criteria. In the Sleep Institute, all vol-
unteers had their height and weight assessed by trained person-
nel for body mass index (BMI) calculation. Medical history was 
evaluated through structured questionnaires, including ques-
tions about smoking and drinking habits and the use of  central 
nervous system (CNS)-acting medication.
Musculoskeletal pain assessment
MSK pain was defined as diffuse pain or pain located in 
the back, joints or limbs as previously described19. The screening 
was accomplished by 2 questions answered at the Sleep Insti-
tute. The first question was: “Did you feel pain over your body, 
associated with tiredness during the day in the last 6 months?” 
with only 2 possible answers: “generally yes” and “generally 
no”. When the volunteer answered “generally yes”, a second 
question about pain location was considered with the following 
possible answers: back, head, chest, over the body, joints, legs, 
mouth, face, teeth and other place.
Subjects who answered back, joints and legs or over the 
body (diffuse pain) were included in the MSK group, while the 
other types of  responses were excluded from the study. Subjects 
that answered “generally no” in the first question and have not 
reported any pain were included as control (CTRL) group. Sub-
jects that did not answer one of  the questions were excluded 
from the study, being considered as missing data (Figure 1).
Somnolence evaluation
Epworth Sleepiness Scale (ESS) was used to assess excessive 
daytime somnolence. It consists in 8 questions involving everyday 
situations20. The patient has to score from 0 to 3 the possibility of  
falling asleep. ESS was validated for use in Brazil, and its use allows 
evaluating the subjective somnolence. In the present study, individ-
uals were considered as having HPS if  they presented ESS score 
higher or equal to 10, and scores of  10-24 represent increasing levels 
of  excessive daytime sleepiness20. Volunteers with scores lower or 
equal to 9 were considered as without HPS.
Groups
According to the evaluation of  pain and somnolence, the 
sample was allocated into 4 groups. CTRL: individuals that had ESS 
score ≤9 and did not report MSK pain; MSK: individuals that had 
ESS score ≤9 and reported MSK pain; HPS: individuals that had 
ESS score ≥10 and did not report MSK pain; HPS+MSK: individu-
als that had ESS score ≥10 and reported MSK pain.
Mood and quality of  life assessments
Anxiety and depression symptoms were assessed by the 
Portuguese validated version of  Beck Anxiety Inventory21 and 
Beck Depression Inventory22, respectively. The quality of  life 
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Figure 1. Flowchart of  the study.  Flowchart illustrates the experimental design of  the study and the inclusion and exclusion criteria. CTRL: individuals without hypersomnolence 
and pain; HPS: individuals with hypersomnolence and no pain; MSK: individuals with pain and no hypersomnolence; HPS+MSK: individuals with both conditions.
was measured by the Portuguese validated version of  the World 
Health Organization Quality of  Life (WHOQoL)-bref23.
Subjective sleep assessment
Sleep quality: To assess the perception of  sleep quality, 
the volunteers completed the Pittsburgh Sleep Quality Index 
(PSQI)24. Cut-off  for PSQI was ≤5 (good sleepers) and >5 
(poor sleepers).
The narcolepsy-related questions below were created by 
a panel of  sleep specialists from the Sleep Institute (São Paulo), 
and were asked by trained instructors with yes/no as answers:
Sleep attacks: The individuals were asked if  they had “un-
controllable sleep attacks, sleeping suddenly” in the last 6 months.
Cataplexy: the cataplectic-like symptom question cov-
ered the occurrence of  an event in the last 6 months. The indi-
viduals were asked if  they had “any event of  sudden weakness 
or difficultly in speaking in situations of  strong emotion (such as 
joy, anger, fear, or surprise) without unconsciousness”.
Objective sleep assessment
All PSG were done at the Sleep Institute (São Paulo, Brazil), 
a sleep laboratory with 80 beds (www.sono.org.br), always respecting 
the usual time the participants went to bed. Participants were asked 
about their sleep routines and wake-up times during the week, at 
weekends and on holidays. The PSG was scheduled according to 
the availability of  the volunteers, and most of  them were performed 
during weekdays (64%). The scheduling of  PSG took into consider-
ation the availability of  the participants.
A type 1 PSG was performed using a digital system (EM-
BLA® N7000, Embla Systems Inc., Broomfield, CO, USA). The 
following physiological tests were performed: electroencepha-
lography (EEG, C3-A2, C4-A1, O1-A2, O2-A1), electrooculog-
raphy (EOG, EOG-Left-A2, EOG-Right-A1), electromyogra-
phy (EMG, muscle of  the submentonian region, tibialis anterior 
muscle, masseter region, and 17th intercostal space), electrocar-
diography (ECG, derivation V1 modified), and airflow detec-
tion by a thermocouple and by nasal pressure. In addition, the 
following physiological parameters were evaluated: respiratory 
effort using thoracic and abdominal x-trace belts, snoring and 
body position by EMBLA sensors, and percutaneous oxygen 
saturation (SpO2) and pulse rate by an EMBLA oximeter. All 
PSG exams were visually scored by a registered and trained 
PSG technologist. All sleep stages were scored according to 
standardized criteria for investigating sleep25. EEG arousals and 
leg movements were scored according to the criteria established 
by the American Academy of  Sleep Medicine (AASM) Manual 
for Scoring Sleep and Associated Events26. Four percent of  the 
PSG results were randomly rescored by a registered PSG tech-
nologist to confirm that all of  the PSG scoring had been ex-
ecuted correctly (agreement rate of  93.36±5.1%, k=0.91±0.03).
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Statistical analysis
All continuous data were tested for normal distribution. 
If  non-parametric, the variables were standardized for loga-
rithmic scale (Log10). Categorical variables were compared us-
ing Pearson chi-square test, and the possible differences were 
identified by the adjusted residual. Continuous parameters were 
compared using two-way analysis of  covariance (ANCOVA), 
considering MSK pain and HPS as fixed factors and control-
ling for age, sex, BMI, use of  CNS-acting medication, alcohol 
consumption and smoking. When significant interaction effect 
between MSK pain and HPS was found, Bonferroni’s post-hoc 
test was applied. Data analysis was performed using SPSS 21 
software (Chicago, IL). All data are presented as mean ± stan-
dard error or percentage within group. The statistical signifi-
cance was set as p<0.05.
RESULTS
From the total sample (n=1,042), 510 met the inclusion 
criteria (Figure 1) and were enrolled in the current study. Of  
these, 55.1% were considered as control without MSK pain 
(CTRL, n=281), 9.8% as control with MSK pain (MSK, n=50), 
27.6% as HPS without MSK pain (HPS, n=141), and 7.5% as 
HPS with MSK pain (HPS+MSK, n=38).
Table 1 demonstrates the comparison of  sociodemo-
graphic parameters among the groups. Groups with MSK 
pain presented higher frequency of  women (MSK 68% and 
HPS+MSK 73.7%), while HPS group presented more men 
(60.3%) when compared to the others. MSK and HPS+MSK 
groups also reported to use more CNS-acting medication. 
Weekly to monthly smoking was significantly associated with 
CTRL 
(n=281)
MSK 
(n=50)
HPS 
(n=141)
HPS+MSK 
(n=38)
p
HPS*MSK 
Age (years) 42.07±15.33 45.56±12.67 42.79±14.01 42.45±15.9 0.265
BMI (kg/m2)a 26.61±5.34 27.43±5.57 27.1±5.06 25.44±5.44 0.066
Gender, %(n)      
Female 45.2 (127) 68.0 (34)§ 39.7 (56) 73.7 (28)§
<0.0001
Male 54.8 (154) 32.0 (16) 60.3 (85)† 26.3 (10)
Monthly income, %(n)     
Low 40.2 (113) 52.0 (26) 29.8 (42) 39.5 (15)
0.160
Medium 47.0 (132) 44.0 (22) 57.4 (81) 50.0 (19)
High 11.0 (31) 2.0 (1) 12.1 (17) 7.9 (3)
Refused to answer 1.8 (5) 2.0 (1) 0.7 (1) 2.6 (1)
Marital status, %(n)b      
Single 32.3 (90) 22 (11) 28.8 (40) 29.7 (11)
0.848
Consensual union 12.2 (34) 10 (5) 11.5 (16) 10.8 (4)
Married 47.3 (132) 64 (32) 48.2 (67) 51.4 (19)
Separated/Divorced 4.7 (13) 2 (1) 7.2 (10) 5.4 (2)
Widower/Widow 3.6 (10) 2 (1) 4.3 (6) 4.3 (6)
Comorbidities     
Diabetesc 6 (17) 8 (4) 5 (7) 0 (0) 0.671
Heart attack 2.1 (6) 0 (0) 0.7 (1) 2.6 (1) 0.747
Neurological disease 4.6 (13) 8 (14) 2.1 (3) 10.5 (4) 0.292
Stroke 1.4 (4) 2 (1) 1.4 (2) 0 (0) 0.940
CNS-acting medication, %(n)d     
Users 34.1 (94) 18 (9)§ 36.5 (50) 63.2 (50)§ <0.0001
Smoking, %(n)      
Weekly to monthly 4.6 (13) 0 (0) 2.8 (4) 15.8 (6)§
0.017
Daily 22.4 (63) 18.0 (9) 22.0 (31) 15.8 (6)
Alcohol consumption, %(n)     
Monthly 18.5 (52) 12.0 (6) 14.2 (20)§ 15.8 (6)
0.043Weekly 38.4 (108) 28.0 (14) 51.1 (72) 36.8 (14)
Daily 7.8 (22) 4.0 (2) 7.10 (10) 7.9 (3)
Table 1. Sample characterization. Sociodemographic and clinical profile of  subjects without hypersomnolence and pain (CTRL), with hypersomnolence 
and no pain (HPS), with pain and no hypersomnolence (MSK) and with both conditions (HPS+MSK) in the EPISONO cohort.
Two-way analysis of  variance (ANOVA), followed by Bonferroni's post hoc test, with data presented by mean ± standard error, or Pearson's Chi-square test with data presented 
by percentage (%) and number of  individuals (n); †observed frequency higher than expected frequency (adjusted residuals higher than 2 and lower than 3); §observed frequency 
higher than expected frequency (adjusted residuals higher than 3).
BMI: body mass index; kg: kilogram; m²: square meter; CNS: central nervous system.
Sample size varied among comparison due to number of  missing data: aMSK n=1; bCTRL=2, HPS n=2, HPS+MSK n=1; cCTRL n=3; dCTRL n=5, HPS n=4.
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HPS+MSK group whilst monthly alcohol consumption was sig-
nificantly associated with HPS group. There was no significant 
difference among the groups considering age, BMI, monthly in-
come, marital status and other comorbidities.
Regarding objective sleep, ANCOVA analysis did not 
demonstrate any interaction effect between MSK pain and HPS 
in sleep parameters (Table 2). The analyses of  total sleep time, 
sleep latency, sleep efficiency, and REM sleep stage showed only 
HPS effect. Groups with HPS had increased total sleep time, 
sleep efficiency and REM sleep as well as lower sleep latency 
compared to those without HPS regardless the presence of  
MSK pain (Table 2).
Table 3 illustrates the subjective indicators of  mood 
symptoms and sleepiness adjusted for confounders. Accord-
ing to the Beck Anxiety Inventory score, we found HPS*MSK 
pain interaction effect (F
1,464
=363.9, p<0.05), showing that MSK 
pain and HPS+MSK groups presented more anxiety symptoms 
than CTRL and HPS groups, respectively. Among MSK pain 
groups, the association with HPS led to significantly higher 
anxiety symptoms. Considering its frequency, there was a sig-
nificant higher prevalence of  moderate to severe anxiety symp-
toms in both HPS+MSK (45.7%) and MSK (30.6%) groups. 
Regarding Beck Depression Inventory score, our results showed 
only isolated effects of  MSK pain and HPS. Nevertheless, 
considering the frequency of  depressive symptoms, we found 
higher prevalence of  moderate to severe depression symptoms 
in HPS+MSK (44.1%), followed by MSK group (18.8%). In 
addition, ANCOVA analysis revealed MSK pain effect on PSQI 
global score. Higher frequency of  poor sleepers was observed in 
HPS+MSK (64.9%) and MSK groups (72.0%).
As expected, the analyzes of  the Epworth Sleepiness 
Scale presented only HPS effect, as both groups with HPS had 
more somnolence compared to those without HPS, regardless 
the presence of  MSK pain (Table 3). The self-report of  sleep 
attacks (64.9%) and cataplexy (34.2%) were significantly associ-
ated with HPS+MSK group compared to the others.
Quality of  life was evaluated according to WHOQoL-
bref  questionnaire, which has 4 domains (Figure 2). Physical 
domain showed HPS*MSK pain interaction effect (F
1,464
=3.6, 
p<0.05) and also isolated effects of  HPS and MSK. Post-hoc 
analysis revealed that both MSK pain and HPS+MSK pain 
groups had lower quality of  life in the physical domain com-
pared to CTRL and HPS groups, respectively. Moreover, among 
MSK pain groups, the presence of  HPS was associated with 
worse physical health quality of  life (Figure 2A). In the psycho-
logical domain, it was observed only MSK pain effect (Figure 
2B). Social domain showed HPS*MSK pain interaction effect 
(F
1,464
=1.3, p<0.05) and also an isolated MSK pain effect. The 
post-hoc analysis demonstrated that both MSK and HPS+MSK 
groups had lower quality of  life in the social domain compared 
to CTRL and HPS, respectively (Figure 2C). Additionally, among 
MSK pain groups, the presence of  HPS was associated with 
worse social quality of  life. Environmental domain presented 
only MSK pain effect (Figure 2D).
 CTRL 
(n=281)
MSK 
 (n=50)
HPS 
(n=141)
HPS+MSK 
(n=38)
p
MSK HPS HPS*MSK
Total sleep time (min) 338.00±4.44 323.96±10.68 351.72±6.31*+ 357.84±12.18*+ 0.665 0.008 0.258
Sleep latency (min) 19.29±1.42 21.64±3.42 14.68±2.02*+ 14.85±3.42*+ 0.667 0.046 0.703
REM sleep latency (min)a 101.23±3.19 107.27±7.62 101.70±4.52 102.96±8.69 0.576 0.763 0.707
Sleep efficiency (%) 80.67±0.72 78.72±1,73 84.46±1.02*+ 83.53±1.97*+ 0.331 0.003 0.720
Stage N1 (%) 4.96±0.22 5.20±0.53 4.24±0.31 4.34±0.61 0.708 0.075 0.866
Stage N2 (%) 54.33±0.55 55.17±1.32 54.51±0.78 55.57±1.51 0.404 0.794 0.923
Stage N3 (%) 21.85±0.48 21.86±1.15 21.57±0.68 20.15±1.32 0.474 0.302 0.457
REM sleep stage (%) 18.86±0.38 17.75±0.91 19.67±0.54*+ 19.95±1.04*+ 0.592 0.049 0.364
Arousal index (number/h) 14.83±0.64 13.00±1.54 16.02±0.91 13.99±1.76 0.145 0.396 0.939
Apnea-hypopnea index (number/h) 7.77±0.71 6.20±1.71 10.44±1.01 5.91±1.95 0.402 0.512 0.712
Basal SpO2 (%) 95.78±0.78 96.17±0.19 95.96±0.11 95.83±0.21 0.403 0.599 0.099
Mean SpO2 (%) 95.05±0.09 95.38±0.21 95.16±0.13 95.13±0.24 0.407 0.683 0.329
Lowest SpO2 (%) 88.75±0.42  89.12±0.71  87.55±0.42  87.98±0.82 0.471 0.061 0.977
Time SpO2<90% (%) 7.05±1.34 7.01±3.17  7.26±1.34  9.83±3.62 0.489 0.080 0.093
Dessaturation index (number/h)b 6.36±0.65 5.09±1.59 8.73±0.92 5.25±1.81 0.084 0.339 0.401
Periodic limb movements (number/h) 1.43±0.32 0.88±0.77 0.49±0.46 1.35±0.88 0.813 0.707 0.275
Table 2. Polysomnographic parameters. Sleep-related parameters adjusted for covariates from subjects without hypersomnolence and pain (CTRL), with 
hypersomnolence and no pain (HPS), with pain and no hypersomnolence (MSK) and with both conditions (HPS+MSK) in the EPISONO cohort.
Two-way analysis of  covariance (ANCOVA), followed by Bonferroni's post hoc test, with data presented by mean ± standard error. Covariates adjusted were: age, sex, body mass 
index, use of  CNS-acting medication, alcohol consumption and smoking. *Statistically different from CTRL group;
#Statistically different from HPS group; +Statistically different from MSK group.
REM: rapid eye movement; SpO2: oxygen saturation.
Sample size varied among comparison due to number of  missing data: aCTRL n=5, HPS n=1; bCTRL=3, HPS n=2; cHPS n-1; dCTRL n=9, HPS n=3; eCTRL n=47, HPS n=22, 
MSK n=9, HPS+MSK n=7.
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Table 3. Anxiety, depression and sleepiness. Symptoms of  anxiety, depression, sleep quality and hypersomnolence-related parameters adjusted for covari-
ates among subjects without hypersomnolence and pain (CTRL), with hypersomnolence and no pain (HPS), with pain and no hypersomnolence (MSK) 
and with both conditions (HPS+MSK) from the EPISONO cohort.
 CTRL 
(n=281)
MSK 
(n=50)
HPS 
(n=141)
HPS+MSK 
 (n=38)
p
MSK HPS HPS*MSK
     
Beck Anxiety Inventorya 5.35±0.43 12.83±1.02* 5.48±0.63 17.67±1.19*#+ <0.0001 0.004 0.007
Minimal anxiety symptoms 81.5 (212)§ 49.0 (24) 80.6 (104)† 28.6 (10)
Mild anxiety symptoms 11.2 (29) 20.4 (10) 17.1 (22) 25.7 (9) <0.0001
Moderate to severe anxiety symptoms 7.3 (19) 30.6 (15)§ 2.3 (3) 45.7 (16)§
Beck Depression Inventoryb 6.51±0.43 14.41±1.02*# 7.54±0.62* 17.04±1.20*# <0.0001 0.035 0.355
Minimal depressive symptoms 88.6 (226)§ 54.2 (26) 84.4 (108) 47.1 (16)
Mild depressive symptoms 7.1 (18) 27.1 (13)§ 10.9 (14) 8.8 (13) <0.0001
Moderate to severe depressive symptoms 4.3 (11) 18.8 (9)† 4.7 (6) 44.1 (15)§
Pittsburgh Sleep Quality Indexc 4.98±0.20 8.32±0.47*# 4.97±0.28 8.24±0.54*# <0.0001 0.908 0.938
Good sleepers 66.1 (181)§ 28.0 (14) 68.8 (97) 35.1 (13)
<0.0001
Poor sleepers 33.9 (93) 72.0 (36)§ 31.2 (44) 64.9 (24)§
Epworth Sleppiness Scale 4.88±0.16 5.59±0.38 12.97±0.23*+ 13.37±0.44*+ 0.079 <0.0001 0.588
Sleep attacks self-report 7.8 (22) 18.0 (9) 19.9 (28)† 64.9 (24)§ <0.0001
Cataplexy self-report 7.9 (22) 14.0 (7) 7.8 (11) 34.2 (13)§ <0.0001
Two-way analysis of  covariance (ANCOVA), followed by Bonferroni's post hoc test, with data presented as mean ± standard error. Covariates adjusted: age, sex, body mass index, 
use of  CNS-acting medication, alcohol consumption and smoking; or Pearson's Chi-square test with data presented as percentage (%) and number of  individuals (n); *Statistically 
different from CTRL group; #Statistically different from HPS group; +Statistically different from MSK group; †observed frequency higher than expected frequency (adjusted 
residuals higher than 2 and lower than 3); §observed frequency higher than expected frequency (adjusted residuals higher than 3).
Sample size varied due to number of  missing data: aCTRL n=26, HPS n=13, MSK n=2, HPS+MSK n=4; bCTRL n=21, HPS n=12, MSK n=1, HPS+MSK n=3; cCTRL n=7, 
HPS+MSK n=1.
Figure 2. Quality of  life. Domains of  World Health Organization Quality of  Life (WHOQoL) questionnaire adjusted for covariates in subjects without hypersomnolence and 
musculoskeletal pain (CTRL), with hypersomnolence and no musculoskeletal pain (HPS), with musculoskeletal pain and no hypersomnolence (MSK) and with both conditions 
(HPS+MSK) from the EPISONO cohort.
*Statistically different from CTRL group; #Statistically different from HPS group; +Statistically different from MSK group. p<0.05.
Sample size varied due to number of  missing data: CTRL n=21, HPS n=12, MSK n=1, HPS+MSK n= 3.
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DISCUSSION
In the current study, we demonstrated an interaction of  
MSK pain and HPS on mood symptoms, as higher frequencies 
of  moderate to severe depression symptoms and higher anxiety 
symptoms were found in the MSK+HPS group compared to 
the MSK alone. The quality of  life of  both physical and so-
cial domains were significantly lower in the MSK+HPS group 
compared to all other groups. It is important to emphasize 
that physical and social well-being were domains impaired by 
MSK pain and/or HPS, and not life quality as a whole. Regard-
ing sleep quality, groups with MSK pain presented worse sleep 
quality, independently of  HPS. Additionally, individuals from 
HPS+MSK group reported higher frequencies of  both sleep at-
tacks and cataplexy, which are narcolepsy-related symptoms. All 
these findings were completely independent from confounders. 
In our sample, the coexistence of  both MSK pain and HPS 
was independently associated with higher levels of  anxiety and de-
pression symptoms, suggesting that the influence of  mood symp-
toms on HPS may depend on MSK pain. Hypersomnolence and 
mood disorders often coexist27. Anxiety and depression symptoms 
are important determinants of  pain intensity and disability in MSK 
pain conditions28. In our investigation, mood disorders were highly 
affected by both MSK pain and HPS factors, independently. Anxi-
ety and depression symptoms have been described as predictors of  
incident HPS in women29, while depression symptoms has been as-
sociated with hypersomnolence in middle-aged adults30. Depression 
seems to play a significant role in MSK pain31 and may be involved 
in the relationship between sleep disorders and the development of  
chronic pain7.
Hypersomnolence was highly prevalent in MSK pain 
(43%) in our adult general population sample, corroborating 
previous literature17. Pain records and perceptions seem to be 
linked to sleep quantity and depression symptoms in narcolepsy 
patients14. Chronic pain was also associated with the incidence 
of  HPS32. In a recent investigation conducted in our group, we 
found that both types of  narcolepsy (types 1 and 2) presented 
a high frequency of  chronic pain (84.84% type 1 versus 75.75% 
type 2), with indistinct pain characteristics between them. In ad-
dition, chronic pain emerged as a co‐morbidity never reported 
before in type 2. Depression possibly influences pain perception 
in these patients33. Narcolepsy comorbidities include chronic 
pain conditions34. The presence of  comorbidities before and 
after narcolepsy was evaluated in another investigation, using a 
clinical database. The authors found that MSK conditions, such 
as low back pain, arthrosis, and arthritis, were conditions emerg-
ing after diagnosis, indicating that narcolepsy increased the in-
cidence of  MKS pain35. Chronic low back pain has increased 
probabilities to occur both at identification and at the end of  a 
9-year observation period of  narcoleptic patients36. Regardless 
of  these results, the scientific evidence is still unfounded as to 
whether pain conditions can act as a cause or consequence of  
narcolepsy37, despite its association.
Higher sleep attacks were also observed in MSK+HPS 
group compared to the other groups, suggesting a possible 
influence of  MSK pain on sleepiness. Sleep has an important 
role in pain processing as sleep disruption has been shown to 
decrease the activity of  the descending inhibitory pain pathways 
in healthy individuals38.
Of  note, one of  our main findings was the interaction 
of  HPS*MSK pain factors found in both the physical and social 
domains of  quality of  life. These results suggest that for both 
domains, the presence of  comorbid HPS in MSK pain may po-
tentiate the impairment on the patient’s quality of  life by modu-
lation of, at least in part, sleep quality and mood symptoms. 
Taking into consideration that 43% of  the MSK pain individuals 
from our cohort presented HPS, defined by Epworth Sleepiness 
Scale score ≥10, our results may indicate a relevant role for HPS 
as a sign of  poor quality of  life in MSK pain-related conditions, 
independently from sleep-disordered breathing, a well-known 
source of  HPS.
Unfortunately, there is no available study to contrast our 
data yet. However, evidence from a clinical trial showed that 
an intervention with hydrotherapy in patients with fibromyalgia 
improved physical function, anxiety and depression symptoms, 
pain intensity, fatigue, and the quality of  life. Moreover, the 
treatment also significantly reduced daytime sleepiness (assessed 
by Epworth Sleepiness Scale)39, indicating an important correla-
tion between the improvement in MSK pain, mood disorders 
and the HPS.
Regarding sleep pattern, our findings showed only HPS-
mediated differences, represented by increased total sleep time, 
sleep efficiency and REM sleep stage, as well as a reduction in 
sleep onset latency in HPS groups compared to no-HPS groups. 
Longer sleep duration was found by Plante et al.40 in patients 
with major depressive disorder and co-occurring HPS, but not 
in controls versus HPS groups, contrary to our findings40. We ob-
served a lack of  differences in objective sleep parameters among 
the groups with and without MSK, differently from subjective 
sleep. Other authors have also addressed inconsistencies among 
objective and subjective sleep quality. In a population-based 
study, subjects with chronic fatigue reported unrefreshing sleep 
and poorer sleep quality more often than non-fatigued con-
trols41. However, there were no significant differences in sleep 
architecture between the groups when measured by PSG41. We 
could speculate that possible changes in sleep architecture could 
be present at a microstructure level, but not macrostructure. 
Currently, the literature about objective sleep and MSK pain 
is very scarce, with most evidence coming from female clinical 
samples and showing shorter sleep duration, lower delta power 
in the EEG of  NREM sleep and higher sleep fragmentation42.
It is important to emphasize that all findings of  the cur-
rent study were adjusted for age, sex, BMI, use of  CNS-act-
ing medication, alcohol consumption and smoking. Moreover, 
there was no influence of  sleep-disordered breathing, another 
potential source of  HPS, as all groups had no differences in all 
sleep-related respiratory parameters. Second, unlike other epide-
miological studies on pain, the enrollment process of  this study 
did not focus on pain, but on a general population18. Thus, the 
possibility of  sampling bias of  individuals who were motivated 
by their pain condition was minimal.
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This study has some limitations. First, we did not have 
an objective measurement of  HPS as its definition was based 
solely on a subjective instrument, the ESS questionnaire. It is 
known that Multiple Sleep Latency Test (MSLT) is considered 
the gold standard measure of  HPS43. Since the primary aim of  
the EPISONO cohort study was not related to HPS, MSLT was 
not performed. However, recent evidence demonstrated diver-
gent associations between subjective and objective HPS and 
depression symptoms in the Wisconsin Sleep Cohort Study44. 
In that cohort, subjective sleepiness, defined by ESS, was associ-
ated with increased odds of  depression symptoms; but MSLT-
measured objective sleep propensity was associated with the op-
posite44. Thus, these data underscore important limitations of  
the MSLT as a measure of  HPS in mood disorders.
Second, besides no significant changes were observed in 
the objective sleep pattern, we must address the lack of  an adap-
tation night due to the epidemiological framework of  the study. 
Third, we cannot ascertain isolated cases of  inaccuracy 
in the self-report of  MSK pain; nevertheless, this issue was ad-
dressed by the population-based method of  the study. Addition-
ally, neither the topography nor the pain intensity were investi-
gated, due to the coexistence of  pain in different body regions 
and lack of  evaluation of  pain intensity.
Fourth, control participants scored on the criteria for 
sleep attack and cataplexy in our sample, as we did not expect 
that. We we assumed that there was a misinterpretation of  the 
volunteers to both questions.
Fifth, the assessment of  MSK pain in this investigation 
was done by a non-validated instrument, as it was measured by 
one question and should be done in further studies by validated 
questionnaires on MSK pain.
Lastly, although there was an association between 
MSK+HPS and worse psychological and well-being param-
eters, we cannot infer causality since the design of  the study was 
cross-sectional. Additional prospective studies and clinical trials 
will be necessary to establish a possible temporal relationship 
between HPS, MSK pain, mood disorders and quality of  life.
CONCLUSIONS
Our study showed that subjects with musculoskeletal 
pain and comorbid hypersomnolence presented a worse clini-
cal picture compared to those without hypersomnolence due to 
higher frequencies of  severe depression, elevated anxiety levels, 
increased prevalence of  sleep attacks and cataplexy, and lower 
quality of  life. This study suggests that the investigation and 
management of  subjective sleepiness may be clinically relevant 
in patients with chronic musculoskeletal pain for a better quality 
of  life.
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